Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the fo...
Saved in:
| Published in: | Journal of translational medicine Vol. 19; no. 1; pp. 272 - 16 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
26.06.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1479-5876, 1479-5876 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients.
Methods
Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals
.
Results
We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts.
Conclusions
We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. |
|---|---|
| AbstractList | Recent studies proposed the whole-blood based IFN-[gamma]-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1[beta], IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-[gamma], IP-10, MCP-1, MIP-1[alpha], MIP-1[beta], PDGF, RANTES, TNF-[alpha], VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. We identified a COVID-19 signature based on six immune factors: IFN-[gamma], IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Methods Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals . Results We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. Conclusions We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Background Recent studies proposed the whole-blood based IFN-[gamma]-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Methods Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1[beta], IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-[gamma], IP-10, MCP-1, MIP-1[alpha], MIP-1[beta], PDGF, RANTES, TNF-[alpha], VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. Results We identified a COVID-19 signature based on six immune factors: IFN-[gamma], IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. Conclusions We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Keywords: SARS-CoV-2, COVID-19, Biomarkers, T-cell, Immunity, IP-10, Whole-blood, Immune response, Spike, IFN-[gamma] Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients.BACKGROUNDRecent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients.Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals.METHODSWhole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals.We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts.RESULTSWe identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts.We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens.CONCLUSIONSWe set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Abstract Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Methods Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. Results We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. Conclusions We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Methods Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. Results We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. Conclusions We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens. |
| ArticleNumber | 272 |
| Audience | Academic |
| Author | Ippolito, Giuseppe Nicastri, Emanuele Petruccioli, Elisa Palmieri, Fabrizio Navarra, Assunta Vanini, Valentina Gualano, Gina Bertoletti, Antonio Goletti, Delia Pierelli, Luca Najafi Fard, Saeid Petrone, Linda Cuzzi, Gilda |
| Author_xml | – sequence: 1 givenname: Elisa surname: Petruccioli fullname: Petruccioli, Elisa organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 2 givenname: Saeid surname: Najafi Fard fullname: Najafi Fard, Saeid organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 3 givenname: Assunta surname: Navarra fullname: Navarra, Assunta organization: Clinical Epidemiology Unit, National Institute for Infectious Disease Lazzaro Spallanzani-IRCCS – sequence: 4 givenname: Linda surname: Petrone fullname: Petrone, Linda organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 5 givenname: Valentina surname: Vanini fullname: Vanini, Valentina organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, UOS Professioni Sanitarie Tecniche National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 6 givenname: Gilda surname: Cuzzi fullname: Cuzzi, Gilda organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 7 givenname: Gina surname: Gualano fullname: Gualano, Gina organization: Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 8 givenname: Luca surname: Pierelli fullname: Pierelli, Luca organization: UOC Transfusion Medicine and Stem Cell Unit, San Camillo Forlanini Hospital – sequence: 9 givenname: Antonio surname: Bertoletti fullname: Bertoletti, Antonio organization: Programme in Emerging Infectious Diseases, Duke-National University of Singapore Medical School – sequence: 10 givenname: Emanuele surname: Nicastri fullname: Nicastri, Emanuele organization: Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 11 givenname: Fabrizio surname: Palmieri fullname: Palmieri, Fabrizio organization: Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS – sequence: 12 givenname: Giuseppe surname: Ippolito fullname: Ippolito, Giuseppe organization: Scientific Direction, National Institute for Infectious Disease “Lazzaro Spallanzani”-IRCCS – sequence: 13 givenname: Delia orcidid: 0000-0001-8360-4376 surname: Goletti fullname: Goletti, Delia email: delia.goletti@inmi.it organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34174875$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ul1rFDEUHaRiP_QP-CADvvgyNcnka16EZam1UBCs-hoySWabdSZZkxlx_33v7rZut0gJIeHmnJPck3NaHIUYXFG8xegcY8k_ZkwaLipEMMymlpV8UZxgKpqKScGPHu2Pi9OclwgRymjzqjiuKRZUCnZShIu_qz4mPca0LnXQ_Tr7XI6x9NaF0Xfrcrx1ZevyCKejX7gAq90X_TBMAfY-Djr9cmnLzeNk1-XN7NtNNY8_K1L60Dkz-hheFy873Wf35n49K358vvg-_1Jdf728ms-uK8ORGCvChe0oshQzIhhjhhnMUStq2TaOo45rbAS1WAtGTIeZ7RCmptVYNpLWHa3Piqudro16qVbJw-vWKmqvtoWYFkqn0ZveKYdZyyk3pBWYutbqumU1Zk5YThhCErQ-7bRWUzs4a8CXpPsD0cOT4G_VIv5RktSsQQQEPtwLpPh7AtfU4LNxfa-Di1NWhFHWNAwjDtD3T6DLOCX4lg2K1TWinMg9aqGhATA3wr1mI6pmXBBwTwoEqPP_oGBYN3gDUeo81A8I7x43-q_Dh7QAQO4AJsWck-uU8aPe_Cso-15hpDbBVLtgKgim2gZTbZ5MnlAf1J8l1TtSBnBYuLR34xnWHavo834 |
| CitedBy_id | crossref_primary_10_3390_v15051146 crossref_primary_10_1016_j_imbio_2023_152755 crossref_primary_10_3389_fimmu_2022_920227 crossref_primary_10_1093_ofid_ofad133 crossref_primary_10_3389_fmed_2023_1271632 crossref_primary_10_1111_ajt_16966 crossref_primary_10_3389_fimmu_2021_740249 crossref_primary_10_1080_08820139_2024_2385992 crossref_primary_10_3390_cells11010052 crossref_primary_10_1371_journal_pone_0283983 crossref_primary_10_3390_sports11050097 crossref_primary_10_3390_vaccines10101601 crossref_primary_10_3389_fimmu_2022_984098 crossref_primary_10_3390_pathogens12070862 crossref_primary_10_3389_fimmu_2022_846753 crossref_primary_10_3390_ijms22168828 crossref_primary_10_3389_fimmu_2023_1244556 |
| Cites_doi | 10.1038/s41591-020-1038-6 10.1183/13993003.01727-2020 10.1126/science.abf4063 10.1084/jem.20202617 10.1016/j.cmi.2020.09.051 10.1016/j.ijid.2021.02.034 10.1016/j.jinf.2021.02.023 10.1126/science.abd7728 10.1038/s41467-020-17292-4 10.1126/sciimmunol.abd2071 10.1016/j.antiviral.2014.06.013 10.1016/j.cell.2020.09.038 10.1111/pim.12499 10.1016/S0140-6736(20)30183-5 10.1016/j.jinf.2014.02.008 10.1016/j.ijid.2021.02.090 10.1016/j.vaccine.2016.02.063 10.1038/s41591-020-1051-9 10.1038/s41586-020-2588-y 10.1111/pim.12695 10.1111/resp.13272 10.1016/j.tube.2018.06.005 10.1016/j.immuni.2020.05.002 10.1038/s41392-020-0148-4 10.4081/idr.2020.8543 10.1186/s12967-015-0513-1 10.1016/j.jcv.2017.03.003 10.1016/j.chom.2020.02.001 10.1016/j.cell.2020.04.026 10.1038/icb.2010.158 10.1007/s40265-020-01421-w 10.1096/fj.201802418R 10.1056/NEJMe2034982 10.1038/s41586-020-2550-z 10.1016/j.cmi.2018.07.017 10.1093/cid/ciaa1537 10.1016/j.jinf.2012.03.017 10.1016/j.ijid.2021.04.034 10.5588/ijtld.16.0342 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12967-021-02938-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_e15b646c2b714ebda3b5315e7d625008 PMC8235902 A672267870 34174875 10_1186_s12967_021_02938_8 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GrantInformation_xml | – fundername: COVID-2020-12371675 grantid: COVID-2020-12371675 – fundername: COVID-2020-12371735 grantid: COVID-2020-12371735 – fundername: Ricerca Corrente linea 1 Infezioni Emergenti e Riemergenti Italian Ministry of Health – fundername: Ricerca Corrente linea 4 Italian Ministry of Health – fundername: COVID 2020-12371675 grantid: COVID 2020-12371675 – fundername: ; – fundername: ; grantid: COVID 2020-12371675 – fundername: ; grantid: COVID-2020-12371735 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-267df40d41527555c5c160b738b9e60f6a1c74d1a752cf15df014cba189843f43 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 23 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000668579000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1479-5876 |
| IngestDate | Fri Oct 03 12:53:23 EDT 2025 Tue Nov 04 01:55:39 EST 2025 Fri Sep 05 08:02:33 EDT 2025 Sun Oct 19 00:04:31 EDT 2025 Tue Nov 11 10:28:24 EST 2025 Tue Nov 04 17:54:46 EST 2025 Thu Jan 02 22:55:26 EST 2025 Tue Nov 18 21:52:00 EST 2025 Sat Nov 29 06:00:41 EST 2025 Sat Sep 06 07:28:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Spike SARS-CoV-2 IFN-γ Immune response T-cell Whole-blood Biomarkers IP-10 Immunity |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-267df40d41527555c5c160b738b9e60f6a1c74d1a752cf15df014cba189843f43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8360-4376 |
| OpenAccessLink | https://doaj.org/article/e15b646c2b714ebda3b5315e7d625008 |
| PMID | 34174875 |
| PQID | 2553304628 |
| PQPubID | 43076 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e15b646c2b714ebda3b5315e7d625008 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8235902 proquest_miscellaneous_2545995106 proquest_journals_2553304628 gale_infotracmisc_A672267870 gale_infotracacademiconefile_A672267870 pubmed_primary_34174875 crossref_citationtrail_10_1186_s12967_021_02938_8 crossref_primary_10_1186_s12967_021_02938_8 springer_journals_10_1186_s12967_021_02938_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-26 |
| PublicationDateYYYYMMDD | 2021-06-26 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAbbrev | J Transl Med |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | JM Dan (2938_CR36) 2021; 371 L Petrone (2938_CR10) 2021; 27 C Rydyznski Moderbacher (2938_CR13) 2020; 183 D Goletti (2938_CR4) 2021; 384 L Petrone (2938_CR32) 2017; 39 W Dammermann (2938_CR33) 2015 K Murugesan (2938_CR20) 2020 JR Groom (2938_CR25) 2011; 89 N Le Bert (2938_CR19) 2020; 584 AG Laing (2938_CR6) 2020; 26 G Echeverría (2938_CR21) 2021; 105 L Tan (2938_CR14) 2020 2938_CR40 L Petrone (2938_CR31) 2020; 42 L Petrone (2938_CR27) 2014; 68 L Petrone (2938_CR26) 2016; 20 DX Liu (2938_CR23) 2014; 109 L Petrone (2938_CR38) 2018; 111 KL Siu (2938_CR24) 2019; 33 D Goletti (2938_CR34) 2018; 23 C Lucas (2938_CR9) 2020; 584 S De Biasi (2938_CR17) 2020 L Petrone (2938_CR12) 2021; 82 DM Del Valle (2938_CR8) 2020; 26 N Le Bert (2938_CR42) 2021; 218 VS Santos (2938_CR29) 2019; 25 E Nicastri (2938_CR41) 2020; 12 D Weiskopf (2938_CR16) 2020; 5 V Vanini (2938_CR30) 2012; 65 A Wu (2938_CR2) 2020; 27 D Blanco-Melo (2938_CR7) 2020; 181 A Wajnberg (2938_CR37) 2020; 370 N Vabret (2938_CR15) 2020; 52 CWM Ong (2938_CR18) 2020; 56 F Cantini (2938_CR3) 2020; 80 L Petrone (2938_CR11) 2021 C Huang (2938_CR5) 2020; 395 A Aiello (2938_CR22) 2021 L Petrone (2938_CR28) 2018; 111 OW Ng (2938_CR35) 2016; 34 WHO (2938_CR1) 2021 MS Hayney (2938_CR39) 2017; 90 |
| References_xml | – volume: 26 start-page: 1623 year: 2020 ident: 2938_CR6 publication-title: Nat Med doi: 10.1038/s41591-020-1038-6 – volume: 56 start-page: 2001727 year: 2020 ident: 2938_CR18 publication-title: Eur Respir J doi: 10.1183/13993003.01727-2020 – volume: 371 start-page: eabf4063 year: 2021 ident: 2938_CR36 publication-title: Science doi: 10.1126/science.abf4063 – volume: 218 start-page: e20202617 year: 2021 ident: 2938_CR42 publication-title: J Exp Med doi: 10.1084/jem.20202617 – volume: 27 start-page: 286.e7 year: 2021 ident: 2938_CR10 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2020.09.051 – volume: 105 start-page: 21 year: 2021 ident: 2938_CR21 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.02.034 – volume: 82 start-page: 58 year: 2021 ident: 2938_CR12 publication-title: J Infect doi: 10.1016/j.jinf.2021.02.023 – volume: 370 start-page: 1227 year: 2020 ident: 2938_CR37 publication-title: Science doi: 10.1126/science.abd7728 – year: 2020 ident: 2938_CR17 publication-title: Nat Commun doi: 10.1038/s41467-020-17292-4 – volume: 5 start-page: eabd2071 year: 2020 ident: 2938_CR16 publication-title: Sci Immunol doi: 10.1126/sciimmunol.abd2071 – volume: 109 start-page: 97 year: 2014 ident: 2938_CR23 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2014.06.013 – volume: 183 start-page: 996 year: 2020 ident: 2938_CR13 publication-title: Cell doi: 10.1016/j.cell.2020.09.038 – volume: 39 start-page: e12499 year: 2017 ident: 2938_CR32 publication-title: Parasite Immunol doi: 10.1111/pim.12499 – volume: 395 start-page: 497 year: 2020 ident: 2938_CR5 publication-title: China Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 68 start-page: 591 year: 2014 ident: 2938_CR27 publication-title: J Infect doi: 10.1016/j.jinf.2014.02.008 – year: 2021 ident: 2938_CR11 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.02.090 – volume: 34 start-page: 2008 year: 2016 ident: 2938_CR35 publication-title: Vaccine doi: 10.1016/j.vaccine.2016.02.063 – volume: 26 start-page: 1636 year: 2020 ident: 2938_CR8 publication-title: Nat Med doi: 10.1038/s41591-020-1051-9 – volume: 584 start-page: 463 year: 2020 ident: 2938_CR9 publication-title: Nature doi: 10.1038/s41586-020-2588-y – volume: 42 start-page: e12695 year: 2020 ident: 2938_CR31 publication-title: Parasite Immunol doi: 10.1111/pim.12695 – volume-title: COVID-19 Clinical management: living guidance year: 2021 ident: 2938_CR1 – volume: 23 start-page: 455 year: 2018 ident: 2938_CR34 publication-title: Respirology doi: 10.1111/resp.13272 – volume: 111 start-page: 147 year: 2018 ident: 2938_CR38 publication-title: Tuberculosis doi: 10.1016/j.tube.2018.06.005 – volume: 52 start-page: 910 year: 2020 ident: 2938_CR15 publication-title: Immunity doi: 10.1016/j.immuni.2020.05.002 – year: 2020 ident: 2938_CR14 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-020-0148-4 – volume: 12 start-page: 8543 year: 2020 ident: 2938_CR41 publication-title: Infect Dis Rep doi: 10.4081/idr.2020.8543 – year: 2015 ident: 2938_CR33 publication-title: J Transl Med doi: 10.1186/s12967-015-0513-1 – volume: 90 start-page: 32 year: 2017 ident: 2938_CR39 publication-title: J Clin Virol doi: 10.1016/j.jcv.2017.03.003 – volume: 27 start-page: 325 year: 2020 ident: 2938_CR2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.02.001 – volume: 181 start-page: 1036 year: 2020 ident: 2938_CR7 publication-title: Cell doi: 10.1016/j.cell.2020.04.026 – volume: 89 start-page: 207 year: 2011 ident: 2938_CR25 publication-title: Immunol Cell Biol doi: 10.1038/icb.2010.158 – volume: 80 start-page: 1929 year: 2020 ident: 2938_CR3 publication-title: Drugs doi: 10.1007/s40265-020-01421-w – volume: 33 start-page: 8865 year: 2019 ident: 2938_CR24 publication-title: FASEB J doi: 10.1096/fj.201802418R – volume: 384 start-page: 867 year: 2021 ident: 2938_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMe2034982 – volume: 111 start-page: 147 year: 2018 ident: 2938_CR28 publication-title: Tuberculosis doi: 10.1016/j.tube.2018.06.005 – volume: 584 start-page: 457 year: 2020 ident: 2938_CR19 publication-title: Nature doi: 10.1038/s41586-020-2550-z – volume: 25 start-page: 169 year: 2019 ident: 2938_CR29 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2018.07.017 – year: 2020 ident: 2938_CR20 publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1537 – ident: 2938_CR40 – volume: 65 start-page: 49 year: 2012 ident: 2938_CR30 publication-title: J Infect doi: 10.1016/j.jinf.2012.03.017 – year: 2021 ident: 2938_CR22 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.04.034 – volume: 20 start-page: 1554 year: 2016 ident: 2938_CR26 publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.16.0342 |
| SSID | ssj0024549 |
| Score | 2.4264677 |
| Snippet | Background
Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of... Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease... Background Recent studies proposed the whole-blood based IFN-[gamma]-release assay to study the antigen-specific SARS-CoV-2 response. Since the early... Recent studies proposed the whole-blood based IFN-[gamma]-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of... Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of... Abstract Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 272 |
| SubjectTerms | Antibody response Antigens Biological markers Biomarkers Biomedical and Life Sciences Biomedicine Blood Chemokines Clinical trials Coronaviruses COVID-19 COVID-19 Vaccines Cytokines Disease Granulocyte colony-stimulating factor Granulocyte-macrophage colony-stimulating factor Growth factors Health aspects Humans Identification and classification Immune response Immunity Immunogenicity ImmunoVirology and ImmunoOncology Infections Infectious diseases Interleukin 10 Interleukin 12 Interleukin 13 Interleukin 2 Interleukin 4 Interleukin 5 Interleukin 6 Interleukin 7 Interleukin 8 Interleukin 9 IP-10 Lymphocytes T Medicine/Public Health Monocyte chemoattractant protein 1 Patients Peptides Proteins RNA, Viral SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 T-cell Tuberculosis Vaccines Variables Vascular endothelial growth factor Viral antigens |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQYgLb0qgoCAhcYCoefiVE1oqKg5QIQpob5btOLASTcruFol_z4zj7JIieuG0UWxr4_ibVzzzGeBZ2dSOM1tl3qC4MWVtZh1HLFvZKNSaaINDofA7eXSk5vP6Q_zgtopplaNODIq66R19I99H15dCb1GqV6c_Mjo1inZX4xEal-EKHZtNOJfzbcDFMPgZC2WU2F-hbUO1QEkJOVo5lamJMQqc_X9r5j9M0_m0yXN7p8EkHd7838ncghvRGU1nA3puwyXf3YFr7-N2-13ohgy9sBGfmkhfkq77dBHKe9tfKbqPqcX_xdY18Xrib7O9uaDiE7xe9CeUBbQMYwOhbXo8-3icHfRfsjId88G6e_D58M2ng7dZPKAhcyKX66wUsmlZ3pATIDnnjrtC5FZWytZe5K0whZOsKYzkpWsL3rQYkDlrClUrVrWsug87Xd_5B5BiYFXlxkhf1Y6ZsjTe5rZFbcLwfXNnEijGldIuspfTIRrfdYhilNDD6mpcXR1WV6sEXmzGnA7cHRf2fk0A2PQk3u1wo19-1VGMtS-4FUy40sqCeduYyqIS4142GEeiO5XAc4KPJu2Aj-dMLHLASRLPlp4Jif4uKckE9iY9UardtHlEjo5aZaW3sEng6aaZRlKmXOf7M-rDiEMOI_0Edge8bqaEsicpQE1ATpA8mfO0pVt8C5zjqqyI6CeBlyPmt4_173f68OJZPILrZZBGgVDag5318sw_hqvu53qxWj4JsvwbZ9tPZg priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BQYgLb0qgoCAhcYCoefiV41JRcYAKdaHqzbIdByLRBO2mSPx7Zpxkl5SHBKdE8VixJ_PwxDOfAZ7lVek4s0XiDaobU9Ym1nGUZSsrhVYTfXAoFH4rj47U6Wn5fiwKW0_Z7tOWZLDUQa2V2F-jZ0KlppSCFH2UStRluILuTtGBDcfLky3CHoY8U3nMb_vNXFBA6v_VHv_kkC4mS17YMQ2O6PDm_03hFtwYF57xYpCU23DJt3fg2rtxa_0utEM2Xth0j80IVRL3XdyEUt76e4xLxdjioLG1JwxPvFbbhw0VmuB9051Rxs8q9A3gtfFycbxMDrqTJI-n3K_2Hnw8fP3h4E0yHsaQOJHKPsmFrGqWVuTwJefccZeJ1MpC2dKLtBYmc5JVmZE8d3XGqxqDL2dNpkrFipoV92Gn7Vr_AGIMoorUGOmL0jGT58bb1NZoORhymTsTQTZ9H-1GpHI6MOOLDhGLEnpgpEZG6sBIrSJ4senzdcDp-Cv1K_rsG0rC2A4PutUnPaqs9hm3ggmXW5kxbytTWDRY3MsKY0ZcOkXwnIRGkyXA4TkzFjTgJAlTSy-ExLUtGcQI9maUqMFu3jyJnR4tyFpjqEe_mkSO73m6aaaelBXX-u6caBjhxWFUH8HuIKWbKaGeSQpGI5Az-Z3Ned7SNp8DvrjKCwL1ieDlJMXbYf2Zpw__jfwRXM-DIggUrT3Y6Vfn_jFcdd_6Zr16EjT6BzSARcI priority: 102 providerName: Springer Nature |
| Title | Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection |
| URI | https://link.springer.com/article/10.1186/s12967-021-02938-8 https://www.ncbi.nlm.nih.gov/pubmed/34174875 https://www.proquest.com/docview/2553304628 https://www.proquest.com/docview/2545995106 https://pubmed.ncbi.nlm.nih.gov/PMC8235902 https://doaj.org/article/e15b646c2b714ebda3b5315e7d625008 |
| Volume | 19 |
| WOSCitedRecordID | wos000668579000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature Link customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RSV dateStart: 20030601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_BQIgXxDeBUQUJiQeIljj-ymM3bQKJVVULU3mybMfRIkGC2g6J_56zk3TLEPDCS9PEtmKf78MX3_0M8JqUhWXU5InTKG5UGpMYy5CXjSglak20wSFR-KOYzeRqVcyvHPXlY8I6eOCOcAcuY4ZTbokRGXWm1LlBtmFOlLhy79N8U1EMztSAsoduz5AiI_nBBq0aKgQfjpCifZOJHJmhgNb_u06-YpSuB0xe2zUNxujkPtzrV5HxtOv9A7jhmodw57TfJ38ETRdaF3bQY93jjsTbNq5DXm71M8Z1X2zw7Vi69YCceC0vH9Y-awT_1-03H76zDm0DEm28nC6WyVF7lpB4CORqHsPnk-NPR--T_mSFxPJUbBPCRVnRtPTWWzDGLLMZT43IpSkcTyuuMytomWnBiK0yVlboSVmjM1lImlc0fwJ7Tdu4ZxCjR5SnWguXF5ZqQrQzqalQDVAkF7M6gmwgtLI97Lg__eKrCu6H5KqbHIWTo8LkKBnB212b7x3oxl9rH_r529X0gNnhAbKR6tlI_YuNInjjZ195scbuWd1nJ-AgPUCWmnKBC1Wv3SLYH9VEcbTj4oF_VK8ONgr9Nv_diBN8z6tdsW_pQ9wa1174OtSDv6GLHsHTjt12Q0KhEd6zjECMGHE05nFJU58HsHBJco_QE8G7gWUvu_Vnmj7_HzR9AXdJEDmODLcPe9v1hXsJt-2Pbb1ZT-CmWInwKydw6_B4Nl9MghDj3fzD6fwL3i2WZ78AZjVHSA |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAL70egQJBAHCBq4ji294DQUqhadVshWtDejO0ksBIkZXcL6p_iNzLjJLukiN564JRVbEeZ5JtvZjYzY4AnLB-4jNs0KgyqG1fWRtZliGUrc4WsiTbYFwqP5N6eGo8H71bgV1cLQ2mVHSd6os5rR_-Rr6PrS6G3YOrV4feIdo2ir6vdFhoNLHaK458Yss1ebr_B9_uUsc23BxtbUburQORELOcREzIveZyT5ZJZlrnMJSK2MlV2UIi4FCZxkueJkRlzZZLlJUYRzppEDRRPS57idc_BeeRxScGeHC8DPI7BVleYo8T6DG0p0hAlQcRoVVWkesbP7xHwtyX4wxSeTNM88a3Wm8DNq__bw7sGV1pnOxw22nEdVorqBlzcbdMJbkLVZCD6RIPQtO1ZwnkdTnz5cnkconscWpQTR-fUtxSP-fLkhIpr8Pek_kZZTlO_1jfsDfeH7_ejjfpjxMIu3626BR_ORNrbsFrVVXEXQgwc09gYWaQDxw1jprCxLZEtOb7fzJkAkg4Z2rXd2WmTkK_aR2lK6AZNGtGkPZq0CuD5Ys1h05vk1NmvCXCLmdRX3J-op591S1O6SDIruHDMyoQXNjepRZLOCpljnIzuYgDPCK6a2A9vz5m2iAOFpD5ieigk-vNkBAJY681E1nL94Q6pumXNmV7CNIDHi2FaSZmAVVEf0RxOPfKSWARwp9GPhUjILZIC8ABkT3N6MvdHqskX31NdsZQaGQXwotOx5W39-5neO12KR3Bp62B3pEfbezv34TLzTCAQVmuwOp8eFQ_ggvsxn8ymDz2PhPDprHXvNzZOqkY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9NAEB5BQRUv3IehgJGQeACrPvbKYyhUIEpUEaj6ttpdryES2FXiIvHvmVnbSV0OCfGUyDureCZzemc-AzzNy4njzBaJN2huTFmbWMdRl60sFXpNjMFhUPhAzmbq-HhyeGaKP3S7D0eS3UwDoTTV7e5JWXUmrsTuCqMUGji1F6QYr1SiLsIlRo30VK_PjzZoe1j-DKMyv903CkcBtf9X33wmOJ1vnDx3ehqC0v61_2fnOlztE9J42mnQDbjg65uw_b4_cr8FddelFw7jY9NDmMRtEy_CiG_1I8YUMrbIAK62hO2Jn-Xm4oIGUPD7ovlGnUDLsDeA2sbz6Yd5stccJXk89ITVt-HT_uuPe2-S_iUNiROpbJNcyLJiaUmJgOScO-4ykVpZKDvxIq2EyZxkZWYkz12V8bLCosxZk6mJYkXFijuwVTe1vwcxFldFaoz0xcQxk-fG29RW6FEYSpw7E0E2_Ffa9Qjm9CKNrzpUMkroTpAaBamDILWK4Pl6z0mH3_FX6pekAmtKwt4OF5rlZ92bsvYZt4IJl1uZMW9LU1h0ZNzLEmtJTKkieEYKpMlD4O050w86IJOEtaWnQmLOS44ygp0RJVq2Gy8PKqh7z7LSWALSIyiR4-88WS_TTuqWq31zSjSMcOSw2o_gbqexa5bQ_iQVqRHIkS6PeB6v1IsvAXdc5QWB_UTwYtDozW39Wab3_438MWwfvtrXB29n7x7AlTzYhEAt24GtdnnqH8Jl971drJaPgqH_BLCFUYo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploratory+analysis+to+identify+the+best+antigen+and+the+best+immune+biomarkers+to+study+SARS-CoV-2+infection&rft.jtitle=Journal+of+translational+medicine&rft.au=Petruccioli%2C+Elisa&rft.au=Najafi+Fard%2C+Saeid&rft.au=Navarra%2C+Assunta&rft.au=Petrone%2C+Linda&rft.date=2021-06-26&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=19&rft.issue=1&rft.spage=272&rft_id=info:doi/10.1186%2Fs12967-021-02938-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |